Pulmonary Arterial Hypertension (PAH) Treatment Market, By Drug Class (Prostacyclin and Prostacyclin Analogs, Phosphodiesterase 5 (PDE 5) Inhibitors, Endothelin Receptor Antagonists (ERA) and Soluble Guanylate Cyclase (SGC) Stimulator), By Route of Administration, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2034
REPORT HIGHLIGHT
The Pulmonary Arterial Hypertension (PAH) Treatment Market was valued at USD 7,980.43 million in 2023 and expanded at a CAGR of 5.90% from 2024 to 2032.
Pulmonary Arterial Hypertension (PAH) is an uncommon yet significant medical condition marked by increased blood pressure within the pulmonary arteries, potentially resulting in heart failure and various other complications. The primary objective of PAH treatment is to alleviate symptoms, enhance the quality of life, and decelerate the progression of the disease. Consistent monitoring of symptoms, functional capacity, and the effectiveness of treatment are essential for the successful management of PAH. Typically, a multidisciplinary team of healthcare professionals, including cardiologists, pulmonologists, and pulmonary medicine specialists, collaborates to provide thorough management of the condition.
Pulmonary Arterial Hypertension (PAH) Treatment Market- Market Dynamics
Increasing Prevalence of Pulmonary Arterial Hypertension (PAH) is anticipated to drive the growth of the market
As the global demographic shifts towards an older population, the prevalence of pulmonary arterial hypertension (PAH) is anticipated to increase, especially among elderly individuals who are more vulnerable to chronic health issues. The rising number of patients with chronic diseases who subsequently develop PAH will likely necessitate comprehensive management approaches, thereby heightening the demand for various treatment alternatives. PAH is classified as a rare condition, with prevalence estimates ranging from 10 to 52 cases per million individuals. According to the European Respiratory Society, PAH (Group 1 pulmonary hypertension) is further divided based on the underlying disease mechanisms. Nevertheless, enhanced investment in clinical research may facilitate the emergence of novel therapies, thereby broadening the market. Conversely, limited awareness among healthcare professionals could hinder market expansion.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
United Therapeutics Ltd.
Bayer AG
Actelion Ltd.
Pfizer, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline plc
Teva Pharmaceuticals Inc.
Eli Lilly and Company
Steady Med Ltd.
Johnson & Johnson Services, Inc.
Others
GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
Prostacyclin and Prostacyclin Analogs
Phosphodiesterase 5 (PDE 5) Inhibitors
Endothelin Receptor Antagonists (ERA)
Soluble Guanylate Cyclase (SGC) Stimulator
GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
Oral
Intravenous/ subcutaneous
Inhalational
GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- The U.S.
- Canada
Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Pulmonary Arterial Hypertension (PAH) Treatment Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Drug Class
2.1.2. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Route of Administration
2.1.3. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Distribution Channel
2.1.4. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Country
2.1.5. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Region
2.2. Competitive Insights
3. Pulmonary Arterial Hypertension (PAH) Treatment Key Market Trends
3.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Pulmonary Arterial Hypertension (PAH) Treatment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Pulmonary Arterial Hypertension (PAH) Treatment Market Opportunities
3.4. Pulmonary Arterial Hypertension (PAH) Treatment Market Future Trends
4. Pulmonary Arterial Hypertension (PAH) Treatment Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Pulmonary Arterial Hypertension (PAH) Treatment Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Pulmonary Arterial Hypertension (PAH) Treatment Market Landscape
6.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Pulmonary Arterial Hypertension (PAH) Treatment Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
7.1.2. Prostacyclin and Prostacyclin Analogs
7.1.3. Phosphodiesterase 5 (PDE 5) Inhibitors
7.1.4. Endothelin Receptor Antagonists (ERA)
7.1.5. Soluble Guanylate Cyclase (SGC) Stimulator
8. Pulmonary Arterial Hypertension (PAH) Treatment Market – By Route of Administration
8.1. Overview
8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
8.1.2. Oral
8.1.3. Intravenous/ subcutaneous
8.1.4. Inhalational
9. Pulmonary Arterial Hypertension (PAH) Treatment Market – By Distribution Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
9.1.2. Hospital Pharmacies
9.1.3. Retail Pharmacies
9.1.4. Online Pharmacies
10. Pulmonary Arterial Hypertension (PAH) Treatment Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Pulmonary Arterial Hypertension (PAH) Treatment Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. United Therapeutics Ltd.
11.2.2. Bayer AG
11.2.3. Actelion Ltd.
11.2.4. Pfizer, Inc.
11.2.5. Gilead Sciences, Inc.
11.2.6. GlaxoSmithKline plc
11.2.7. Teva Pharmaceuticals Inc.
11.2.8. Eli Lilly and Company
11.2.9. Steady Med Ltd.
11.2.10. Johnson & Johnson Services, Inc.
11.2.11. Others
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
